Promising NMOSD attack treatment trial pulled before it began
NCT ID NCT06673394
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study aimed to test the drug eculizumab for people having an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a condition where the immune system attacks the central nervous system. The trial planned to give four weekly doses of eculizumab alongside standard steroids to reduce disability. However, the study was withdrawn before enrolling any participants, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- eculizumab
- What this could lead to
- If this approach had been tested, it might have pointed toward a faster way to treat acute NMOSD attacks by blocking harmful immune activity.
- What could go wrong
- The trial was withdrawn before enrolling anyone, so no results exist. Eculizumab also raises infection risk, especially from meningococcal bacteria.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.